ReviewPharmacoEconomics2006
Cost-of-illness studies : a review of current methods.
Review in PharmacoEconomics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 15 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 15 syntheses or guidelines pooled it.
- Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.PharmacoEconomics · 2021Pooled it
- Cost of Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic Review of Cost-of-Illness Studies.PharmacoEconomics · 2020Pooled it
- Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review.PharmacoEconomics · 2020Pooled it
- The cost of mental disorders: a systematic review.Epidemiology and psychiatric sciences · 2020Pooled it
- The excess costs of depression: a systematic review and meta-analysis.Epidemiology and psychiatric sciences · 2019Pooled it
- Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review.BMC health services research · 2018Pooled it
- [Socioeconomic Costs of Asthma in the European Union, United States and Canada: A Systematic Review].Revista espanola de salud publica · 2017Pooled it
- Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.PharmacoEconomics · 2016Pooled it
- The Economic Costs of Type 2 Diabetes: A Global Systematic Review.PharmacoEconomics · 2015Pooled it
- Economics of Malignant Gliomas: A Critical Review.Journal of oncology practice · 2015Pooled it
- Cost of illness in colorectal cancer: an international review.PharmacoEconomics · 2013Pooled it
- How are the costs of drug-related morbidity measured?: a systematic literature review.Drug safety · 2012Pooled it
- Economic burden of multiple sclerosis: a systematic review of the literature.PharmacoEconomics · 2010Pooled it
- Cost of illness of glaucoma: a critical and systematic review.PharmacoEconomics · 2009Pooled it
- The costs of treating breast cancer in the US: a synthesis of published evidence.PharmacoEconomics · 2009Pooled it
- Excess costs of mental disorders by level of severity.Social psychiatry and psychiatric epidemiology · 2023Trial
- Healthcare costs of foodborne diseases in the United States: an analysis using electronic health records.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Estimation of Costs Related to the Management of Herpes Zoster and its Complications in Vietnam: A Medical Chart Review.Infectious diseases and therapy · 2026Article
- Opening the Discussion on the Costs of Pedophilic Disorder as a Mental Health Concern.Archives of sexual behavior · 2026Article
- Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of cost-of-illness (COI) studies has expanded considerably over time. One outcome of this growth is that the reported COI estimates are inconsistent across studies, thereby raising concerns over the validity of the estimates and methods. Several factors have been identified in the literature as reasons for the observed variation in COI estimates. To date, the variation in the methods used to calculate costs has not been examined in great detail even though the variations in methods are a major driver of variation in COI estimates. The objective of this review was to document the variation in the methodologies employed in COI studies and to highlight the benefits and limitations of these methods. The review of COI studies was implemented following a four-step procedure: (i) a structured literature search of MEDLINE, JSTOR and EconLit; (ii) a review of abstracts using pre-defined inclusion and exclusion criteria; (iii) a full-text review using pre-defined inclusion and exclusion criteria; and (iv) classification of articles according to the methods used to calculate costs. This review identified four COI estimation methods (Sum_All Medical, Sum_Diagnosis Specific, Matched Control and Regression) that were used in categorising articles. Also, six components of direct medical costs and five components of indirect/non-medical costs were identified and used in categorising articles.365 full-length articles were reflected in the current review following the structured literature search. The top five cost components were emergency room/inpatient hospital costs, outpatient physician costs, drug costs, productivity losses and laboratory costs. The dominant method, Sum_Diagnosis Specific, was a total costing approach that restricted the summation of medical expenditures to those related to a diagnosis of the disease of interest. There was considerable variation in the methods used within disease subcategories. In several disease subcategories (e.g. asthma, dementia, diabetes mellitus), all four estimation methods were represented, and in other cases (e.g. HIV/AIDS, obesity, stroke, urinary incontinence, schizophrenia), three of the four estimation methods were represented. There was also evidence to suggest that the strengths and weaknesses of each method were considered when applying a method to a specific illness. Comparisons and assessments of COI estimates should consider the method used to estimate costs both as an important source of variation in the reported COI estimates and as a marker of the reliability of the COI estimate.
Indexed as
Identifiers
16942122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.